Gabather AB (publ) (GABA.ST)
SEK 0.4
(-3.61%)
SEK 0.4
(-3.61%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.65 SEK | -3.17% |
| 2022 | -0.63 SEK | 50.39% |
| 2021 | -1.27 SEK | -15.45% |
| 2020 | -1.10 SEK | 28.57% |
| 2019 | -1.54 SEK | 60.91% |
| 2018 | -3.94 SEK | -104.15% |
| 2017 | -1.93 SEK | 10.65% |
| 2016 | -2.16 SEK | -8.0% |
| 2015 | -2.00 SEK | -85.19% |
| 2014 | -1.08 SEK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.18 SEK | 10.0% |
| 2024 Q2 | -0.09 SEK | 50.5% |
| 2023 Q3 | -0.19 SEK | -72.73% |
| 2023 Q2 | -0.11 SEK | 26.67% |
| 2023 Q1 | -0.15 SEK | 16.67% |
| 2023 Q4 | -0.20 SEK | -5.26% |
| 2023 FY | - SEK | 0.0% |
| 2022 Q4 | -0.18 SEK | -20.0% |
| 2022 Q1 | -0.14 SEK | 66.67% |
| 2022 Q2 | -0.15 SEK | -7.14% |
| 2022 Q3 | -0.15 SEK | 0.0% |
| 2022 FY | - SEK | 50.39% |
| 2021 Q4 | -0.42 SEK | -50.0% |
| 2021 FY | - SEK | -15.45% |
| 2021 Q1 | -0.26 SEK | -4.0% |
| 2021 Q2 | -0.31 SEK | -19.23% |
| 2021 Q3 | -0.28 SEK | 9.68% |
| 2020 Q4 | -0.25 SEK | 24.24% |
| 2020 FY | - SEK | 28.57% |
| 2020 Q3 | -0.33 SEK | -65.0% |
| 2020 Q1 | -0.32 SEK | 54.29% |
| 2020 Q2 | -0.20 SEK | 37.5% |
| 2019 Q2 | -0.81 SEK | -12.5% |
| 2019 Q4 | -0.70 SEK | -32.08% |
| 2019 Q3 | -0.53 SEK | 34.57% |
| 2019 FY | - SEK | 60.91% |
| 2019 Q1 | -0.72 SEK | 10.0% |
| 2018 Q3 | -1.00 SEK | 15.97% |
| 2018 Q4 | -0.80 SEK | 20.0% |
| 2018 FY | - SEK | -104.15% |
| 2018 Q1 | -1.46 SEK | -67.82% |
| 2018 Q2 | -1.19 SEK | 18.49% |
| 2017 Q4 | -0.87 SEK | -625.0% |
| 2017 Q2 | -0.70 SEK | -11.11% |
| 2017 Q1 | -0.63 SEK | 0.0% |
| 2017 FY | - SEK | 10.65% |
| 2017 Q3 | -0.12 SEK | 82.86% |
| 2016 Q1 | -0.52 SEK | -15.56% |
| 2016 FY | - SEK | -8.0% |
| 2016 Q2 | -0.61 SEK | -17.31% |
| 2016 Q4 | -0.63 SEK | -28.57% |
| 2016 Q3 | -0.49 SEK | 19.67% |
| 2015 Q2 | -0.66 SEK | -34.69% |
| 2015 Q3 | -0.41 SEK | 37.88% |
| 2015 Q4 | -0.45 SEK | -9.76% |
| 2015 FY | - SEK | -85.19% |
| 2015 Q1 | -0.49 SEK | -22.5% |
| 2014 Q2 | -0.01 SEK | 0.0% |
| 2014 Q4 | -0.40 SEK | 4.76% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q3 | -0.42 SEK | -8300.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AcuCort AB | -0.16 SEK | -306.25% |
| AlzeCure Pharma AB (publ) | -0.60 SEK | -8.333% |
| BioGaia AB (publ) | 3.62 SEK | 117.956% |
| Enzymatica AB (publ) | -0.28 SEK | -132.143% |
| Enorama Pharma AB (publ) | -1.61 SEK | 59.627% |
| Klaria Pharma Holding AB (publ.) | -0.36 SEK | -80.556% |
| Moberg Pharma AB (publ) | -1.33 SEK | 51.128% |
| Nanexa AB (publ) | -1.09 SEK | 40.367% |
| Newbury Pharmaceuticals AB (publ) | -0.72 SEK | 9.722% |
| ODI Pharma AB | 0.02 SEK | 2877.778% |
| Orexo AB (publ) | -3.73 SEK | 82.574% |
| Probi AB (publ) | 1.48 SEK | 143.919% |
| Swedencare AB (publ) | 0.37 SEK | 275.676% |
| Swedish Orphan Biovitrum AB (publ) | 7.47 SEK | 108.701% |
| Toleranzia AB | -0.06 SEK | -1060.714% |
| Vivesto AB | -0.74 SEK | 12.162% |